| ID Source | ID |
|---|---|
| PubMed CID | 5702238 |
| CHEMBL ID | 1321398 |
| CHEBI ID | 183404 |
| SCHEMBL ID | 136062 |
| MeSH ID | M000609992 |
| Synonym |
|---|
| AC-13152 |
| smr001233305 |
| MLS002153966 , |
| PRESTWICK_9 |
| 25155-18-4 |
| methylbenzthonium chloride |
| methyl benzethonium chloride |
| methylbenzethonium chloride |
| NCGC00095032-01 |
| NCGC00164393-01 |
| NCGC00095032-02 |
| SPECTRUM1503253 |
| NCGC00095032-04 |
| NCGC00095032-03 |
| HMS2093A07 |
| HMS502B21 |
| HMS1922M21 |
| HMS1570M11 |
| CHEBI:183404 |
| benzyl-dimethyl-[2-[2-[2-methyl-4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]azanium;chloride |
| 101912-16-7 |
| HMS2097M11 |
| quat 20 |
| quat20 |
| nn7590iuqx , |
| benzenemethanaminium, n,n-dimethyl-n-(2-(2-(2-methyl-4-(1,1,3,3-tetramethylbutyl)phenoxy)ethoxy)ethyl)-, chloride |
| benzyldimethyl(2-(2-((4-(1,1,3,3-tetramethylbutyl)-o-tolyl)oxy)ethoxy)ethyl)ammonium chloride |
| unii-nn7590iuqx |
| pharmakon1600-01503253 |
| nsc-758427 |
| nsc758427 |
| HMS2235G10 |
| CHEMBL1321398 |
| AKOS015961180 |
| CCG-39322 |
| n,n-dimethyl-n-(2-[2-(methyl-4-[1,1,3,3-tetramethylbutyl]phenoxy)ethoxy]ethyl)benzylammonium chloride |
| FT-0628864 |
| ammonium, benzyldimethyl(2-(2-((4-(1,1,3,3-tetramethylbutyl)-o-tolyl)oxy)ethoxy)ethyl)-, chloride |
| benzenemethanaminium, n,n-dimethyl-n-(2-(2-(2-methyl-4-(1,1,3,3-tetramethylbutyl)phenoxy)ethoxy)ethyl)-, chloride (1:1) |
| HMS3371P01 |
| SCHEMBL136062 |
| methylbenzethoniumchloride |
| QWZLBLDNRUUYQI-UHFFFAOYSA-M |
| SR-05000002081-1 |
| SR-05000002081-3 |
| sr-05000002081 |
| AC9659 |
| J-015841 |
| HMS3714M11 |
| mfcd00011821 |
| AS-15749 |
| Q27284969 |
| benzenemethanaminium, n,n-dimethyl-n-[2-[2-[methyl-4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]-, chloride (1:1) |
| benzyldimethyl[2-[2-[[4-(1,1,3,3-tetramethylbutyl)tolyl]oxy]ethoxy]ethyl]ammonium chloride |
| n-benzyl-n,n-dimethyl-2-[2-[2-methyl-4-(2,4,4-trimethyl-2-pentyl)phenoxy]ethoxy]ethanaminium chloride |
| SY264361 |
| n-benzyl-n,n-dimethyl-2-(2-(2-methyl-4-(2,4,4-trimethylpentan-2-yl)phenoxy)ethoxy)ethanaminium chloride |
| F72663 |
| n-benzyl-n,n-dimethyl-2-(2-(2-methyl-4-(2,4,4-trimethylpentan-2-yl)phenoxy)ethoxy)ethan-1-aminium chloride |
| F90388 |
| methylbenzethonium chloride, reference standard |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Imiquimod (5-10 microg/ml) combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0." | ( Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Bazarsky, E; El-On, J; Sneir, R, 2007) | 0.34 |
| Class | Description |
|---|---|
| alkylbenzene | A monocyclic arene that is benzene substituted with one or more alkyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 15.7143 | 0.0447 | 17.8581 | 100.0000 | AID485294; AID485341 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 63.0957 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 35.4813 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| TDP1 protein | Homo sapiens (human) | Potency | 2.6069 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.3872 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| Smad3 | Homo sapiens (human) | Potency | 14.1254 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 15.8489 | 0.0002 | 14.3764 | 60.0339 | AID588533 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 44.6684 | 0.0008 | 17.5051 | 59.3239 | AID588544 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 50.1187 | 0.0002 | 29.3054 | 16,493.5996 | AID588513 |
| 67.9K protein | Vaccinia virus | Potency | 10.1331 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 39.8107 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 22.3872 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 50.1187 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 23.1093 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 125.8920 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 41.0074 | 0.7943 | 21.2757 | 50.1187 | AID624246; AID651803 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 65.1308 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| enteropeptidase precursor | Homo sapiens (human) | Potency | 19.9526 | 3.1623 | 8.1369 | 10.0000 | AID493169 |
| nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 89.1251 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 19.0849 | 0.6561 | 9.4520 | 25.1189 | AID463254; AID493168; AID927 |
| snurportin-1 | Homo sapiens (human) | Potency | 65.1308 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 12.5893 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.1474 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| geminin | Homo sapiens (human) | Potency | 5.8675 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 3.9811 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 70.7946 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 15.8489 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 3.9811 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 12.5893 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Potency | 25.1189 | 0.0158 | 23.5273 | 44.6684 | AID651778 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 15.8489 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | IC50 (µMol) | 60.6500 | 0.0375 | 18.6232 | 53.2000 | AID588524; AID588538 |
| caspase-9 isoform alpha precursor | Homo sapiens (human) | IC50 (µMol) | 39.1000 | 0.0256 | 16.5070 | 52.8000 | AID588574 |
| ubiquitin-conjugating enzyme E2 N | Homo sapiens (human) | IC50 (µMol) | 9.2060 | 0.8730 | 10.7219 | 78.4000 | AID493155; AID493182 |
| caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 39.1000 | 0.0256 | 20.3235 | 74.3000 | AID588574 |
| bcl-2-related protein A1 | Mus musculus (house mouse) | IC50 (µMol) | 14.9000 | 0.4190 | 7.7563 | 35.1000 | AID504689 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | AC50 | 7.5570 | 0.1950 | 3.6679 | 18.6960 | AID540270 |
| DNA repair protein RAD52 homolog isoform a | Homo sapiens (human) | AC50 | 20.4000 | 0.1500 | 12.0662 | 35.2100 | AID652116 |
| heat shock protein 90, putative | Plasmodium falciparum 3D7 | AC50 | 7.8030 | 0.1950 | 4.9920 | 98.5000 | AID540268 |
| hypothetical protein CAALFM_CR05890CA | Candida albicans SC5314 | AC50 | 32.7000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| H3 histone acetyltransferase | Candida albicans SC5314 | AC50 | 32.7000 | 1.5500 | 13.0038 | 54.7000 | AID588764 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 22 (41.51) | 18.7374 |
| 1990's | 12 (22.64) | 18.2507 |
| 2000's | 7 (13.21) | 29.6817 |
| 2010's | 11 (20.75) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (8.77%) | 5.53% |
| Reviews | 3 (5.26%) | 6.00% |
| Case Studies | 5 (8.77%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 44 (77.19%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||